EXTEND DISEASE-FREE SURVIVAL

WITH THE FIRST AND ONLY ADJUVANT TARGETED TREATMENT FOR ALK+ NSCLC1,2

ALECENSA significantly reduced the risk of disease recurrence or death by 76% compared 
with platinum-based chemotherapy2

ALINA disease-free survival: ITT (Stage IB–IIIA)2,*

94%

 of patients are DISEASE FREE AT Year 2 with ALECENSA2

ALINA disease-free survival: ITT (Stage IB–IIIA)2,*

ALINAmobileversiongraphs_DFSITT(StageIB–IIIA)

Median survival follow-up was 27.8 months for ALECENSA and 28.4 months for chemotherapy2

 ITT (Stage IB–IIIA)2,*
Stage II-IIIA ALK+ NSCLC2,*
 ALECENSA
Chemotherapy
ALECENSA
Chemotherapy
Patient number, n
130127116115
Median disease-free survival (95% CI), months
NE (95% CI: NE, NE)
41.3 (95% CI: 28.5, NE)
NE (95% CI: NE, NE)
44.4 (95% CI: 28.7, NE)
Disease-free survival HR (95% CI)
HR=0.24 (95% CI: 0.13, 0.43), p<0.001
HR=0.24 (95% CI: 0.13, 0.45), p<0.001
 
 
 

OS data were not mature at the time of the primary DFS analysis with 2.3% of deaths reported overall2

Discover

ALECENSA IN

ALK+ RESECTED NSCLC

*Stage IB (tumours ≥4 cm), II or IIIA NSCLC classified according to the 7th edition of the UICC/AJCC.2

 

AJCC: American Joint Committee on Cancer; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; DFS: disease-free survival; HR: hazard ratio; ITT: intention-to-treat; NE: not estimable; NSCLC: non-small cell lung cancer; OS: overall survival; SmPC: Summary of Product Characteristics; UICC: Union for International Cancer Control.


1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276.

ALECENSA provided CONSISTENT DFS BENEFIT across Stage IB through to Stage IIIA2,*

Discover

ALECENSA IN

ALK+ RESECTED NSCLC

 

*These subgroup analyses are exploratory and not powered to demonstrate statistical significance between treatment arms and should therefore be interpreted with caution. †Stage IB (tumours ≥4 cm), II or IIIA NSCLC classified according to the 7th edition of the UICC/AJCC.2

 

AJCC: American Joint Committee on Cancer; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; DFS: disease-free survival; HR: hazard ratio; NSCLC: non-small cell lung cancer; SmPC: Summary of Product Characteristics; UICC: Union for International Cancer Control.


1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276.

brain

Patients with ALK+ NSCLC are at high risk for brain metastases, which are associated with poor prognosis and have a substantial effect on health-related quality of life2

ALECENSA significantly reduced the risk of disease recurrence or death by 76% compared 
with platinum-based chemotherapy2

ALINA: CNS-DFS ITT (Stage IB–IIIA)2,3,†

alina-cns
ALINAmobileversiongraphs_CNS-DFSITT(StageIB–IIIA)

Median survival follow-up was 27.8 months for ALECENSA and 28.4 months for chemotherapy2

CNS-DFS ITT2
ALECENSA
Chemotherapy
Patient number, n
130127
Patients with event, n6
18
Death2
4
Brain recurrence414
CNS-DFS HR (95% CI)
HR=0.22 (95% CI: 0.08, 0.58)
  • CNS-DFS is defined as the time from randomisation to the first documented recurrence of disease in the CNS or death from any cause2

Discover

ALECENSA IN

ALK+ RESECTED NSCLC

*This analysis is exploratory and not powered to demonstrate statistical significance between treatment arms and should therefore be interpreted with caution. †Stage IB (tumours ≥4 cm), II or IIIA NSCLC classified according to the 7 edition of the UICC/AJCC.2

 

AJCC: American Joint Committee on Cancer; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; DFS: disease-free survival; HR: hazard ratio; ITT: intention-to-treat; NSCLC: non-small cell lung cancer; SmPC: Summary of Product Characteristics; UICC: Union for International Cancer Control.


1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276; 3. Solomon BJ, et al. Presented at the European Society for Medical Oncology Congress, 20–24 October 2023, Madrid, Spain.